Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis

NCT05641298 is registered in ClinicalTrials.gov with Aceragen as lead sponsor.

NCT NCT05641298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05641298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Lead sponsor
Aceragen
Phase
Phase 2
Overall status
Withdrawn
Start date
February 10, 2023
Completion date
September 30, 2023
Enrollment
0 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, cystic fibrosis pulmonary exacerbation